A decrease in glucagon-like peptide 2 (GLP-2) derived from intestinal L cells is observed in GVHD patients and mice, and teduglutide (a GLP-2 agonist) treatment facilitates PC regeneration, thus benefiting AMP expression and microbiota control against GVHD (124). This evidence concerns the gene GCG and graft versus host disease.